Literature DB >> 15138201

Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease.

W J Sandborn1, E V Loftus.   

Abstract

Patients with moderate to severely active Crohn's disease treated with infliximab may have a small but real risk of developing severe infections, opportunistic infections, and non-Hodgkin's lymphoma.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15138201      PMCID： PMC1774089          DOI： 10.1136/gut.2003.020552

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  36 in total

1.  Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration.

Authors:  S Lori Brown; Mark H Greene; Sharon K Gershon; Evelyne T Edwards; M Miles Braun
Journal:  Arthritis Rheum       Date:  2002-12

2.  Extracolonic malignancies in inflammatory bowel disease.

Authors:  A Ekbom; C Helmick; M Zack; H O Adami
Journal:  Cancer       Date:  1991-04-01       Impact factor: 6.860

3.  European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment.

Authors:  H Malchow; K Ewe; J W Brandes; H Goebell; H Ehms; H Sommer; H Jesdinsky
Journal:  Gastroenterology       Date:  1984-02       Impact factor: 22.682

4.  Mortality in inflammatory bowel disease: a population-based cohort study.

Authors:  Tim Card; Richard Hubbard; Richard F A Logan
Journal:  Gastroenterology       Date:  2003-12       Impact factor: 22.682

5.  Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County.

Authors:  T Ljung; P Karlén; D Schmidt; P M Hellström; A Lapidus; I Janczewska; U Sjöqvist; R Löfberg
Journal:  Gut       Date:  2004-06       Impact factor: 23.059

6.  Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis.

Authors:  R G Farmer; G Whelan; V W Fazio
Journal:  Gastroenterology       Date:  1985-06       Impact factor: 22.682

7.  Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study.

Authors:  D H Present; B I Korelitz; N Wisch; J L Glass; D B Sachar; B S Pasternack
Journal:  N Engl J Med       Date:  1980-05-01       Impact factor: 91.245

8.  The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients.

Authors:  Jean-Frederic Colombel; Edward V Loftus; William J Tremaine; Laurence J Egan; W Scott Harmsen; Cathy D Schleck; Alan R Zinsmeister; William J Sandborn
Journal:  Gastroenterology       Date:  2004-01       Impact factor: 22.682

9.  Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.

Authors:  C S J Probert; S D Hearing; S Schreiber; T Kühbacher; S Ghosh; I D R Arnott; A Forbes
Journal:  Gut       Date:  2003-07       Impact factor: 23.059

10.  Infliximab maintenance therapy for fistulizing Crohn's disease.

Authors:  Bruce E Sands; Frank H Anderson; Charles N Bernstein; William Y Chey; Brian G Feagan; Richard N Fedorak; Michael A Kamm; Joshua R Korzenik; Bret A Lashner; Jane E Onken; Daniel Rachmilewitz; Paul Rutgeerts; Gary Wild; Douglas C Wolf; Paul A Marsters; Suzanne B Travers; Marion A Blank; Sander J van Deventer
Journal:  N Engl J Med       Date:  2004-02-26       Impact factor: 91.245
View more
  13 in total

1.  Role of interleukin 6 in a murine model of Crohn's ileitis: are cytokine/anticytokine strategies the future for IBD therapies?

Authors:  T T Pizarro; S A De La Rue; F Cominelli
Journal:  Gut       Date:  2006-09       Impact factor: 23.059

2.  Perioperative anti-tumor necrosis factor therapy does not increase the rate of early postoperative complications in Crohn's disease.

Authors:  Basil S Nasir; Eric J Dozois; Robert R Cima; John H Pemberton; Bruce G Wolff; William J Sandborn; Edward V Loftus; David W Larson
Journal:  J Gastrointest Surg       Date:  2010-09-25       Impact factor: 3.452

3.  Down-regulation of interferon-gamma parallels clinical response to selective leukocyte apheresis in patients with inflammatory bowel disease: a 12-month follow-up study.

Authors:  V Muratov; J Lundahl; A K Ulfgren; K Elvin; I Fehrman; N Ahlborg; A Ost; N Hittel; A Saniabadi; R Löfberg
Journal:  Int J Colorectal Dis       Date:  2006-03-15       Impact factor: 2.571

4.  Medical management of Crohn's disease.

Authors:  Paul A Feldman; Daniel Wolfson; Jamie S Barkin
Journal:  Clin Colon Rectal Surg       Date:  2007-11

5.  Risk of haematopoietic cancer in patients with inflammatory bowel disease.

Authors:  J Askling; L Brandt; A Lapidus; P Karlén; M Björkholm; R Löfberg; A Ekbom
Journal:  Gut       Date:  2005-05       Impact factor: 23.059

6.  Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study.

Authors:  L Biancone; A Orlando; A Kohn; E Colombo; R Sostegni; E Angelucci; F Rizzello; F Castiglione; L Benazzato; C Papi; G Meucci; G Riegler; C Petruzziello; F Mocciaro; A Geremia; E Calabrese; M Cottone; F Pallone
Journal:  Gut       Date:  2005-08-24       Impact factor: 23.059

Review 7.  Cancer in inflammatory bowel disease.

Authors:  Jianlin Xie; Steven H Itzkowitz
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

8.  Infliximab administration prior to surgery does not increase surgical site infections in patients with ulcerative colitis.

Authors:  Motoi Uchino; Hiroki Ikeuchi; Hiroki Matsuoka; Toshihiro Bando; Kaoru Ichiki; Kazuhiko Nakajima; Naohiro Tomita; Yoshio Takesue
Journal:  Int J Colorectal Dis       Date:  2013-04-21       Impact factor: 2.571

Review 9.  Clinical pharmacokinetics and use of infliximab.

Authors:  Ulrich Klotz; Alexander Teml; Matthias Schwab
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

Review 10.  Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease.

Authors:  Frank Hoentjen; Ad A van Bodegraven
Journal:  World J Gastroenterol       Date:  2009-05-07       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.